 |
Daniel L. Peters
Chairman of the Board, Non-executive director, Phadia
Mr. Peters was appointed to the board of the Phadia Group in 2008.
Mr. Peters was most recently President and CEO of global Medical Diagnostics at GE Healthcare and a corporate officer of GE, retiring from the company at the end of 2007. He previously served as COO at Amersham Health, as the global President for Amersham Health’s Medical Diagnostics business, and as the President of Nycomed Amersham Imaging Inc. He has also served as President of the Americas for the pharmaceuticals business of Hafslund Nycomed and as President of the US pharmaceutical business of Sterling Winthrop Inc.
Mr. Peters holds a B.Sc. degree from Western Illinois University. |
 |
Magnus Lundberg
Chief Executive Officer, Phadia
Mr. Lundberg was appointed to the board of Pharmacia Diagnostics (now Phadia) Group in 2004. Since March 1999 he has served as President and Chief Executive Officer of Pharmacia Diagnostics/Phadia.
Between 1996 and 1999 Mr. Lundberg served as President of both Chiron Therapeutics and Chiron Vaccines, each a division of Chiron Corporation. From 1981 to 1996 he held various management positions at Pharmacia AB.
Mr. Lundberg holds an M.Sc. in Biology and Biochemistry from Åbo Akademi in Turku, Finland. |
|
|
Stuart McAlpine
Non-executive director, Phadia
Mr. McAlpine was appointed to the board of Phadia Group in January 2006. He is a partner at Cinven and joined in 1996. He has been involved in a number of transactions including Amadeus, Phadia, World Directories, Unique Pub Company, Foseco and Fitness First. He is a member of the Healthcare and TMT sector teams and is also a board member of Amadeus.
He was previously with the Royal Bank of Scotland in their Leveraged Finance Group, having moved there from Ernst & Young, where he worked in Boston and London.
Mr. McAlpine has a degree in Accountancy from Glasgow University. |
 |
Supraj Rajagopalan
Non-executive director, Phadia
Dr. Rajagopalan was appointed to the board of Phadia Group in January 2006. He joined Cinven in 2004 and has worked on a number of transactions including Spire Healthcare, Ahlsell, Partnerships in Care and Phadia. He is a member of the Healthcare and Industrial sector teams.
Dr. Rajagopalan was previously at Boston Consulting Group, where he worked on projects in the Financial Service and Healthcare sectors. Prior to this, he was a doctor in the UK National Health Service.
Dr. Rajagopalan graduated from Cambridge University with undergraduate and postgraduate degrees in Medical Sciences. |
 |
Lars Holmqvist
Employee representative, Phadia
Mr. Holmqvist was appointed to the board of Pharmacia Diagnostics Group in 2004. He joined the company in 1981 and started his career within Research & Development and changed position to Sales & Marketing in 1991. At present he is International Product Manager for ImmunoCAP instruments.
Mr. Holmqvist holds a degree in Chemical Engineering. |
 |
Anna-Tora Martin
Employee representative, Phadia
Mrs. Martin was appointed to the board of Pharmacia Diagnostics Group in 2004. She joined the company in 1982 as a scientist and has since held a number of positions before being appointed Environmental Manager in 2006.
Mrs. Martin has a Ph.D. in Chemistry.
|